Thanks! You've successfully subscribed to the BONEZONE®/OMTEC® Monthly eNewsletter!

Please take a moment to tell us more about yourself and help us keep unwanted emails out of your inbox.

Choose one or more mailing lists:
BONEZONE/OMTEC Monthly eNewsletter
OMTEC Conference Updates
Advertising/Sponsorship Opportunities
Exhibiting Opportunities
* Indicates a required field.

RoosterBio Launches Umbilical Cord hMSC System for Cell Therapy Product Development

RoosterBio launched a human umbilical cord (hUC) MSC paired cell and media system designed for regenerative medicine product development. The RoosterVial™-hUC-MSC-XF allows scientists to generate billions of perinatal cells in a fraction of the time compared to the company's existing xeno-free hMSC plug and play systems. This product line is the only commercially available, high-volume perinatal MSC bioprocess system with a line of sight to towards clinical translation.

“Until now, there was not a hUC-MSC on the market that would support the quality and scale needs of cell therapy product developers,” said RoosterBio Founder & Chief Product Officer Jon A. Rowley, Ph.D. RoosterBio’s launch of RoosterVial-hUC-MSC-XF introduces another first-in-class hMSC product on the market that simplifies all aspects of product development. 

The adoption of umbilical cord hMSC product development in Asia and Europe has demonstrated hUC-MSCs are the fastest growing tissue type and second in overall usage within hMSC Regenerative Medicine applications. hUC-MSC product development in North America has been slower to develop due to the lack of availability of this critical raw material.

RoosterBio announced the collaboration with Tissue Regeneration Therapeutics in May 2019 which gave RoosterBio an exclusive worldwide license to TRT’s patent estate related to the manufacture and global sale of hUC-derived MSCs. 

 Source: RoosterBio Inc.